Significant decrease in rate of sebum production in patients receiving low-dose oral isotretinoin
MONDAY, Oct. 31, 2016 (HealthDay News) — For patients with moderate-to-severe seborrhea and seborrheic dermatitis, low-dose oral isotretinoin can be therapeutic, according to a study published online Oct. 25 in the International Journal of Dermatology.
Cristhine de Souza Leão Kamamoto, M.D., Ph.D., from the Universidade Federal de São Paulo in Brazil, and colleagues determined the efficacy and safety of low-dose oral isotretinoin in the treatment of moderate-to-severe seborrhea and seborrheic dermatitis on the scalp and/or face. Over six months the trial was conducted in two groups: Patients in Group ISO received isotretinoin 10 mg every other day; patients in Group X received antiseborrheic topical treatment.
There were 45 patients with a mean age of 28.7 ± 5.8 years in Group ISO and 29.8 ± 6.5 years in Group X. The researchers observed a significant decrease in the rate of sebum production in Group ISO. In both groups, patient opinion, investigator, and quality of life assessments improved.
“Low-dose oral isotretinoin can be a therapeutic modality for moderate to severe seborrhea and seborrheic dermatitis,” the authors write.
Germed Pharma donated the oral isotretinoin; L’Oréal Brasil and Galderma Brasil donated the topical products.
Full Text (subscription or payment may be required)
Copyright © 2016 HealthDay. All rights reserved.
